Skip to main content
. 2015 Aug 14;10(8):e0135673. doi: 10.1371/journal.pone.0135673

Fig 3. Subgroup analyses of overall survival for oxaliplatin followed by irinotecan-based regimens versus the reverse sequence.

Fig 3

The overall hazard ratio (HR) for oxaliplatin followed by irinotecan-based regimens (arm A) versus the reverse sequence (arm B) was 1.06 (95% confidence interval [CI]: 0.95−1.19; p = 0.27). Age, gender, hypertension, diabetes, hyperlipidemia, cardiovascular disease, and chronic kidney disease were not independently associated with better overall survival in patients receiving either chemotherapy sequence.